**Stakeholder Workshop: Action Plans to Achieve Vision 2025**

**12 September | 13:20 – 14:30 ICT**

|  |
| --- |
| **Biopharmaceutical Companies and Industry Associations** Instructions: 1. Following the presentations on the industry association annual reports on code of ethics implementation, Sabrina will introduce the biopharmaceutical industry association workshop (overview the instructions) for the action plans to achieve Vision 2025.
2. Small groups of 4 people each will then move into Studio 3 and 4 rooms.
3. Each group will fill out the worksheet below and discuss the key questions among their group.
4. When time is up at 14:30, groups will join back in the Great Room (hollow square) to highlight key topic areas in the summary discussion. Sabrina will begin the discussion when called upon to share insights from the biopharmaceutical sector.
 |

Facilitator:

Sabrina Chan, Hong Kong Association of the Pharmaceutical Industry, Ethics & Business Integrity Committee (eBIC), IFPMA

|  |  |  |  |
| --- | --- | --- | --- |
| Vision 2025 Statement  | Vision 2025 Actions  | Current Progress  | Next Steps in Your Organization to Realize Vision 2025 |
| For the Medical Device and Biopharmaceutical Industry: Code of ethics adoption by all medical device and biopharmaceutical industry organizations by 2021. | * Convene a multi-stakeholder, dual-sector team to outreach to and provide active support for industry organizations that have not yet adopted a code of ethics.
* The APEC Biopharmaceutical Working Group on Ethics may also advise on strategies to achieve this goal, including a communications strategy.
* Complete annual survey and report on code of ethics adoption by medical device and biopharmaceutical industry organizations and report the results to the APEC SME Working Group for review and comment. Transmit the results to governments and the public, as appropriate, to highlight where code adoption successes and gaps may remain.
 |  |  |
| For the Medical Device and Biopharmaceutical Industry: Code of ethics implementation by all medical device and biopharmaceutical industry organizations by 2025, realized through member enterprise adherence rates of 100% for every industry association code. | * Convene a multi-stakeholder expert team to outreach to and provide active support for industry organizations seeking to strengthen code of ethics implementation, including governance, alignment with the APEC Principles, member enterprise adherence, and external stakeholder engagement.
* Complete annual survey and report on code of ethics implementation by medical device and biopharmaceutical industry organizations and report the results to the APEC SME Working Group for review and comment. Transmit the results to governments and the public, as appropriate, to highlight where code implementation successes and gaps may remain.
* Provide a code of ethics compendium and toolkit for each sector to help companies, including SMEs, implement high standard ethical business practices. The compendiums may contain a website link to each industry organization’s code of ethics as well as an annual statement from each industry organization affirming their code of ethics aligns with the APEC Principles.

APEC SME Leaders in Ethics and Integrity Program (LEIP) * Convene APEC SME LEIP seminars in partnership with industry organizations across a majority of APEC economies by 2025. APEC SME LEIP supports member enterprise adherence to industry organization codes of ethics by fostering “tone-at-the-top” by the leaders of individual SMEs, providing them with dedicated capacity-building and an international network.
* Pilot two APEC SME LEIP seminars in 2020, assessing the modules and effectiveness through user feedback and industry organization assessment on implementation needs.
* Develop APEC SME LEIP Masterclass, including such materials as business leader testimonials, case studies, and decision-making frameworks.
* Collect examples of code certification, complaint proceedings, or other enforcement mechanisms by APEC medical device and biopharmaceutical industry organizations. The Overseer may showcase these examples to other interested industry groups in support of their code implementation activities and efforts to realize the goal of 100% member enterprise adherence.
* Once the examples of code certification have been collected, the Overseer may convene an expert working group to pilot the creation of a code certification resource.
 | * What training activities around the code is your association planning in the next 2 years?
* Has your association created a code of conduct ethics committee to address code of conduct issues?
* Do you have an example of code certification to share with the initiative (e.g. code training or certification from the association)?
* Do you have examples of a case study of the impact of your code of conduct?
* How do you communicate with external stakeholders and internal stakeholders on your ethics program?
* Are there areas of importance that are not mentioned that should be focused on?
 |  |